https://www.selleckchem.com/pr....oducts/pexidartinib-
Our analysis suggests that VOCs have a medium-sized effect on pulmonary diseases, including the onset of asthma (effect size (or Cohen's d) ~0.37; 95% confidence interval (CI) = 0.25-0.49; n = 23) and wheezing (effective size ~0.26; 95% CI = 0.10-0.42; n = 1. The effect size also varied by country, age and disease type. Multiple stakeholders must be engaged in strategies to mitigate and manage VOC exposure and its associated pulmonary disease burden.We propose a model for cohesin-mediated loop extrusion, where the loop ex